RX Biosyent Inc

The Board of Directors of BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased
to announce the appointment of Paul R. Montador to the Company's Board. 


Mr. Montador brings to BioSyent Inc. over 35 years of experience in healthcare
product sales, marketing, leadership and corporate governance. At present, he is
the CEO (founder) of InspiAir Inc. and Chairman of the Board of
ThinkFirst/Pensez d'Abord Canada, a national non-profit organization dedicated
to the prevention of brain and spinal cord injuries. Over the last 20 years Mr.
Montador's roles have also included CEO of SciCan Inc., President of Johnson &
Johnson Medical Products (Canada), President and Board member of Amsco Inc.
(acquired by Steris Corporation), Vice-President and General Manager of American
Hospital Supply (Canada) (acquired by Baxter Corp.) and Board member of CryoCath
Technologies Inc. (acquired by Medtronic, Inc.).


BioSyent Inc. also announces the grant of 25,000 incentive stock options to a
Director of the Company. These incentive stock options are exercisable at a
price of $0.50 up to December 15, 2016.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada. The
Company is focused on medications that occupy a niche in the market, that are
unique either due to complexity of manufacture or provide novel technological or
therapeutic advantages, or that are backed by strong partners holding
intellectual property rights that are defendable. This strategy allows the
Company to market these medications as brands owned by, or licensed to, it.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024